Preclinical Testing of the Nitroimidazopyran PA-824 for Activity against Mycobacterium tuberculosis in a Series of In Vitro and In Vivo Models
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
This study extends earlier reports regarding the in vitro and in vivo efficacies of the nitroimidazopyran PA-824 against Mycobacterium tuberculosis . PA-824 was tested in vitro against a broad panel of multidrug-resistant clinical isolates and was found to be highly active against all isolates (MIC < 1 μg/ml). The activity of PA-824 against M. tuberculosis was also assessed grown under conditions of oxygen depletion. PA-824 showed significant activity at 2, 10, and 50 μg/ml, similar to that of metronidazole, in a dose-dependent manner. In a short-course mouse infection model, the efficacy of PA-824 at 50, 100, and 300 mg/kg of body weight formulated in methylcellulose or cyclodextrin/lecithin after nine oral treatments was compared with those of isoniazid, rifampin, and moxifloxacin. PA-824 at 100 mg/kg in cyclodextrin/lecithin was as active as moxifloxacin at 100 mg/kg and isoniazid at 25 mg/kg and was slightly more active than rifampin at 20 mg/kg. Long-term treatment with PA-824 at 100 mg/kg in cyclodextrin/lecithin reduced the bacterial load below 500 CFU in the lungs and spleen. No significant differences in activity between PA-824 and the other single drug treatments tested (isoniazid at 25 mg/kg, rifampin at 10 mg/kg, gatifloxacin at 100 mg/kg, and moxifloxacin at 100 mg/kg) could be observed. In summary, its good activity in in vivo models, as well as its activity against multidrug-resistant M. tuberculosis and against M. tuberculosis isolates in a potentially latent state, makes PA-824 an attractive drug candidate for the therapy of tuberculosis. These data indicate that there is significant potential for effective oral delivery of PA-824 for the treatment of tuberculosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Disseminated tuberculosis in interferon gamma gene-disrupted mice.
Cooper, A. M., Dalton, D. K., Stewart, T. A., Griffin, J. P., Russell, D. G., & Orme, I. M. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.6.2243 · Cited by 1,986
Self-citationWayne, L. G., & Hayes, L. G. (1996) · Infection and Immunity · doi:10.1128/iai.64.6.2062-2069.1996 · Cited by 1,141 · cited 9×
“tuberculosis was grown under conditions of transient oxygen depletion by use of a slightly modified version of the protocol first developed by Wayne and Hayes (26).”
BackgroundMethodInfluentialA small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis
Stover, C. K., Warrener, P., VanDevanter, D. R., Sherman, D. R., Arain, T. M., Langhorne, M. H., Anderson, S. W., Towell, J. A., Yuan, Y., McMurray, D. N., et al. (2000) · Nature · doi:10.1038/35016103 · Cited by 1,034
Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis
Brennan, P. J. (2003) · Tuberculosis · doi:10.1016/s1472-9792(02)00089-6 · Cited by 884
Search for New Drugs for Treatment of Tuberculosis
Program*, T. D. S. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.7.1943-1946.2001 · Cited by 223
Stead, W. W. (1967) · PubMed · doi:10.1164/arrd.1967.95.5.729 · Cited by 206
Susceptibility testing of slowly growing mycobacteria by a microdilution MIC method with 7H9 broth
Wallace, R. J., Nash, D. R., Steele, L. C., & Steingrube, V (1986) · Journal of Clinical Microbiology · doi:10.1128/jcm.24.6.976-981.1986 · Cited by 192
Drugs that Inhibit Mycolic Acid Biosynthesis in Mycobacterium tuberculosis
SCHROEDER, E., de Souza, O. N., dos Santos, D. K. C., Blanchard, J. S., & Basso, L. A. (2002) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201023378328 · Cited by 181
Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis
Kelly, B. P., Furney, S. K., Jessen, M., & Orme, I. M. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.12.2809 · Cited by 111
Self-citationChoi, K.-P., Kendrick, N., & Daniels, L. (2002) · Journal of Bacteriology · doi:10.1128/jb.184.9.2420-2428.2002 · Cited by 108
Choi, K.-P., Bair, T., Bae, Y.-M., & Daniels, L. (2001) · Journal of Bacteriology · doi:10.1128/jb.183.24.7058-7066.2001 · Cited by 96
Controlling multidrug-resistant tuberculosis and access to expensive drugs: a rational framework.
(2002) · Europe PMC (PubMed Central) · Cited by 95
Metronidazole Therapy in Mice Infected with Tuberculosis
Brooks, J. V., Furney, S. K., & Orme, I. M. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.5.1285 · Cited by 91
Self-citationThe search for new sterilizing anti-tuberculosis drugs
Denis, A. M. (2004) · Frontiers in bioscience · doi:10.2741/1293 · Cited by 89
Bactericidal activity of nitrofurans against growing and dormant Mycobacterium bovis BCG
Murugasu-Oei, B. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/46.6.917 · Cited by 87
Activity of Quinolones Against Mycobacteria
Jacobs, M. R. (1999) · Drugs · doi:10.2165/00003495-199958002-00004 · Cited by 86
Antitubercular Isoniazid and Drug Resistance of Mycobacterium tuberculosis — A Review
Scior, T., Morales, I. M., Garcés‐Eisele, S. J., Domeyer, D. M., & Laufer, S. (2002) · Archiv der Pharmazie · doi:10.1002/ardp.200290005 · Cited by 66
Mycobacteria: General Culture Methodology and Safety Considerations
Allen, B. W. (2003) · Humana Press eBooks · doi:10.1385/0-89603-471-2:15 · Cited by 65
Reaven, G. M. (1999) · Drugs · doi:10.2165/00003495-199958001-00006 · Cited by 49
Predictive In Vitro Models of the Sterilizing Activity of Anti-Tuberculosis Drugs
Mitchison, D., & Coates, A. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043383269 · Cited by 49
Cited by
Hurdle, J. G., O'Neill, A. J., Chopra, I., & Lee, R. E. (2011) · Nature Reviews Microbiology · doi:10.1038/nrmicro2474 · Cited by 871
Antituberculosis drugs: Ten years of research
Janin, Y. L. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.01.030 · Cited by 485
Drug Resistance Mechanisms in Mycobacterium tuberculosis
Palomino, J., & Martin, A. (2014) · Antibiotics · doi:10.3390/antibiotics3030317 · Cited by 442
Diarylquinolines Are Bactericidal for Dormant Mycobacteria as a Result of Disturbed ATP Homeostasis
Koul, A., Vranckx, L., Dendouga, N., Balemans, W., Van den Wyngaert, I., Vergauwen, K., Göhlmann, H. W. H., Willebrords, R., Poncelet, A., Guillemont, J., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m803899200 · Cited by 364
A replication clock for Mycobacterium tuberculosis
Gill, W. P., Harik, N. S., Whiddon, M. R., Liao, R. P., Mittler, J. E., & Sherman, D. R. (2009) · Nature Medicine · doi:10.1038/nm.1915 · Cited by 341
“This has been a considerable barrier to understanding latent tuberculosis, and efforts to develop new therapies generally assume that the bacteria are very slowly replicating or nonreplicating during latenc”
Background
Metadata
- Authors
- Lenaerts, A. J., Gruppo, V., Marietta, K. S., Johnson, C. M., Driscoll, D. K., Tompkins, N. M., Rose, J. D., Reynolds, R. C., & Orme, I. M.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2005-06
- Volume
- 49
- Issue
- 6
- Pages
- 2294-2301
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W1977671952
- Cited by
- 306
- References
- 20
- FWCI
- 10.20
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.